• Explore /
  • Poster
  • / A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.

A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.

Abstract Poster

Authors

null

Chengyuan Gu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

Chengyuan Gu , Ruju Wang , Huizhu Kang , Xuefeng He , Jun Chen , Zhihong Lin , Yuejun Liu , Ting Yang , Depei Wu , Yue Han

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT05654194

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 6545)

DOI

10.1200/JCO.2024.42.16_suppl.6545

Abstract #

6545

Poster Bd #

104

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: Hartmut Dohner

First Author: William Joseph Chapin

First Author: Amer Methqal Zeidan